Publisher
Petro Mohyla Black Sea National University
Reference9 articles.
1. Garkavi LKh, Kvakina EB, Kuzmenko TS. Antistressornye reaktsii i aktivatsionnaya terapiya. M: Imedis, 1998. 655 s. [Russian]
2. Garkavi LKh, Shikhlyarova AN, Barsukova LM, i dr. Vzaimootnoshenie opukholi i organizma pri razvitii razlichnykh nespetsificheskikh adaptatsionnykh reaktsiy. Tezisy dokladov II sezda onkologov stran SNG. Kiev, 2000. s. 39. [Russian]
3. Perevodchikova NI. Protivoopukholevaya khimioterapiya. M: Meditsina, 2015. 376 s. [Russian] Aghajanian C, Finkler N, Rutherford T, Smith DA, Yi J, Parmar H, Nycum LR, Sovak MA. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarien (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Clin Oncol. 2012; 29: Abstr. LBA5007. Burger R, Brady M, Bookman M, Walker JL, Homesley HD, Fowler J, Monk BJ, et al. Phase III trial of bevacizumab (bev) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol. 2012; 28: Abstr. LBA 1.
4. Asadollahi R, Hyde C, Zhong X. Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol. Oncol. 2013; 118 (1): 81-7. https://www.ncbi.nlm.nih.gov/pubmed/20421130. https://doi.org/10.1016/j.ygyno.2010.03.015
5. Diagnosis and treatment of ovarian cancer.;Best;Nurs Times,2009